Delcath Systems Inc (DCTH)

Currency in USD
11.020
-0.430(-3.76%)
Closed·
11.0200.000(0.00%)
·
DCTH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.01011.690
52 wk Range
8.12017.352
Key Statistics
Prev. Close
11.45
Open
11.49
Day's Range
11.01-11.69
52 wk Range
8.12-17.352
Volume
274.73K
Average Volume (3m)
399.66K
1-Year Change
-31.5953%
Book Value / Share
3.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DCTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.793
Upside
+88.69%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Delcath Systems Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.793
(+88.69% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy18.00+63.34%20.00Maintain27/02/2026
Clear Street
Buy27.00+145.01%29.00Maintain26/02/2026
BTIG
Buy19.00+72.41%23.00Maintain26/02/2026
Stephens
Buy18.00+63.34%25.00Maintain05/11/2025
Craig-Hallum
Buy20.00+81.49%24.00Maintain21/10/2025

Delcath Systems Inc Earnings Call Summary for Q1/2026

  • Delcath Systems Q1 2026 revenue reached $25M, up 26.3% YoY, beating forecast of $23.51M; EPS of -$0.03 topped estimates by 70%.
  • HEPZATO KIT drove 93.2% of revenue with 86% gross margin; company posted $1.1M net loss versus $1.1M income in Q1 2025.
  • Stock rose 1.95% pre-market to $11.48 following earnings beat; shares up 32% over six months with analyst targets reaching $29.76.
  • Company revised 2026 guidance, lowering active metastatic uveal melanoma treatment center target to 37 from previous projections.
  • CEO Padia emphasized expanding treatment network and commercial footprint; CHOPIN trial results driving increased physician adoption of therapies.
Last Updated: 13/05/2026, 20:34
Read Full Transcript

Earnings

Latest Release
07/05/2026
EPS / Forecast
-0.03 / -0.10
Revenue / Forecast
25M / 23.51M
EPS Revisions
Last 90 days

Compare DCTH to Peers and Sector

Metrics to compare
DCTH
Peers
Sector
Relationship
P/E Ratio
678.1x−8.9x−0.5x
PEG Ratio
6.71−0.180.00
Price/Book
3.4x4.3x2.6x
Price / LTM Sales
4.2x3.1x3.1x
Upside (Analyst Target)
73.6%64.2%51.6%
Fair Value Upside
Unlock14.9%6.0%Unlock

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
5.44M15.75%59.93M
Other Institutional Investors
17.25M49.96%190.06M
Public Companies & Retail Investors
11.84M34.29%130.45M
Total
34.52M100.00%380.43M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Rosalind Opportunities Fund I L.P10.23%3,530,21538,903
Rosalind Advisors, Inc.9.56%3,300,38936,370

People Also Watch

4.94
OPRX
0.00%
33.98
PRDO
+0.59%
29.57
BLKB
-0.17%
34.73
VCEL
-1.19%
76.46
CHEF
-2.07%

FAQ

What Is the Delcath Systems (NASDAQ: DCTH) Share Price Today?

The Delcath Systems stock price today is 11.020 USD.

What Stock Exchange Does Delcath Systems (DCTH) Trade On?

Delcath Systems is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Delcath Systems?

The stock symbol (also called a 'ticker') for Delcath Systems is "DCTH."

What Is the Current Delcath Systems Market Capitalisation?

As of today, Delcath Systems (NASDAQ: DCTH) market cap is 380.430M USD.

What Is Delcath Systems's (DCTH) Earnings Per Share (TTM)?

The Delcath Systems EPS is currently 0.014 (Trailing Twelve Months).

When Is the Next Delcath Systems Earnings Date?

Delcath Systems's next earnings report will be released on 10/08/2026.

Is DCTH a Buy or Sell From a Technical Analyst Perspective?

Based on today's Delcath Systems moving averages and other technical indicators, the daily buy/sell signal for DCTH stock is Strong Buy.

How Many Times Has Delcath Systems Stock Split?

Delcath Systems has split 5 times. (See the DCTH stock split history page for full effective split date and price information.)

How Many Employees Does Delcath Systems Have?

Delcath Systems has 156 employees, based on their latest Companies House report.

What is the current trading status of Delcath Systems (NASDAQ: DCTH)?

As of 24/05/2026, Delcath Systems (DCTH) is trading at a share price of 11.020 USD, with a previous close of 11.450 USD. The stock has fluctuated within a day range of 11.010 USD to 11.690 USD, while its 52-week range spans from 8.120 USD to 17.352 USD.

What Is Delcath Systems (DCTH) Price Target According to Analysts?

The average 12-month price target for Delcath Systems is 20.793 USD, with a high estimate of 29.76 USD and a low estimate of 16 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +88.69% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.